JP Morgan Chase
CGON icon

JP Morgan Chase’s CG Oncology CGON Stock Holding History

JP Morgan Chase’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31M Sell
417,726
-141,860
-25% -$9.27M ﹤0.01% 1854
2026
Q1 		$35.8M Sell
559,586
-27,243
-5% -$1.54M ﹤0.01% 1610
2025
Q4 		$24.4M Buy
586,829
+358,950
+158% +$14.9M ﹤0.01% 1892
2025
Q3 		$9.18M Buy
227,879
+173,785
+321% +$5.05M ﹤0.01% 2797
2025
Q2 		$1.41M Sell
54,094
-68,088
-56% -$1.64M ﹤0.01% 4162
2025
Q1 		$2.99M Sell
122,182
-46,684
-28% -$1.31M ﹤0.01% 3574
2024
Q4 		$4.84M Buy
168,866
+137,795
+443% +$4.71M ﹤0.01% 3373
2024
Q3 		$1.17M Buy
31,071
+11,542
+59% +$405K ﹤0.01% 4367
2024
Q2 		$617K Buy
19,529
+9,991
+105% +$346K ﹤0.01% 4564
2024
Q1 		$419K Buy
+9,538
New +$390K ﹤0.01% 4905

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase's CGON Position: Q2 2026 in Review

JP Morgan Chase reduced its CG Oncology (CGON) stake by 25% in Q2 2026, selling an estimated $9.27M and leaving 417,726 shares worth $31M. The position accounts for ﹤0.01% of the portfolio, ranked #1854.

JP Morgan Chase first reported a position in CGON in Q1 2024 and has held it in 10 quarters since. The position peaked at $35.8M in Q1 2026. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • JP Morgan Chase held 417,726 shares of CG Oncology worth $31M as of Q2 2026.
  • JP Morgan Chase sold 141,860 CG Oncology shares in Q2 2026, an estimated $9.27M.
  • CG Oncology made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #1854 holding.
  • JP Morgan Chase first reported a position in CG Oncology in Q1 2024 and has held it in 10 quarters since.
  • JP Morgan Chase's CG Oncology position peaked at $35.8M in Q1 2026.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.